---
slug: tirzepatide-metformin
title: "tirzepatide metformin"
kind: standard
status: published
hash: da8dbe60536d76b06f8223341aa20d7b838a62a040f428dffb53e70f6890b1d2
created: 2026-06-29T17:29:32.453Z
updated: 2026-10-08T11:49:35.092Z
summary: "Evidence is being populated by Grok web"
tags: []
above: []
below: []
adjacent: []
nested: []
---
# tirzepatide metformin

*Evidence is being populated by Grok web*

## Overview
Evidence is being populated by Grok web search.

## Facts

```json
{
  "converted_from": "markdown",
  "original_updated": "2026-06-29T17:29:33.355Z",
  "register": "standard",
  "category": null
}
```

## Sources

1. [Long-term efficacy and safety of tirzepatide in participants with type 2 diabetes with inadequate glycaemic control on metformin and/or sulfonylurea: Post-hoc analysis of SURPASS-4](https://pubmed.ncbi.nlm.nih.gov/40926359/) — “Tirzepatide significantly improved glycaemic control and body weight reduction compared to insulin glargine over 104 weeks in participants with type 2 diabetes inadequately controlled on metformin and/or sulfonylurea. The safety profile of tirzepatide was acceptable, with a lower incidence of hypoglycaemia than insulin glargine.” (sha256 00804df440b46d76)
2. [Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study](https://pubmed.ncbi.nlm.nih.gov/39796271/) — “The results indicate that combining 1 mM metformin with either 10 nM semaglutide or 10 nM tirzepatide significantly enhances the effects of 10 nM semaglutide and 10 nM tirzepatide on HG-HL-induced apoptosis and dysregulated cell cycle. Specifically, the combination treatments demonstrated superior restoration of glucose-stimulated insulin secretion (GSIS) functionality compared to 1 mM metformin, 10 nM semaglutide, and 10 nM tirzepatide.” (sha256 b9cbea575dd36f4b)
3. [Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes : A Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/42184419/) — “In participants with early T2D uncontrolled with metformin, tirzepatide treatment resulted in superior reductions in HbA1c, weight, and waist circumference, and more participants achieved normoglycemia (HbA1c <5.7%) with tirzepatide than ICC after 2 years.” (sha256 6327ab4d4da5b365)